As part of the LMB-365 project, Michel Goedert was recognised this week for 35 years at LMB (The Medical Research Council Laboratory of Molecular Biology) focussing on the study of Alzheimer’s disease, helping to show that the aggregation of tau protein is sufficient to cause neurodegeneration and dementia. LMB 365 – Day 336.
This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking (www.imi.europa.eu) under grant agreement No 116060. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 17.00038.
The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.